Cefadroxil indications and usage: Difference between revisions
Created page with "__NOTOC__ {{Cefadroxil}} {{CMG}} ==Indications And Usage== DURICEF is indicated for the treatment of patients with infection caused by susceptible strains of the designated o..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cefadroxil}} | {{Cefadroxil}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Indications and Usage== | |||
DURICEF is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: | DURICEF is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: | ||
| Line 12: | Line 13: | ||
Pharyngitis and/or tonsillitis caused by [[Streptococcus pyogenes]] (Group A beta-hemolytic [[streptococci]]). | Pharyngitis and/or tonsillitis caused by [[Streptococcus pyogenes]] (Group A beta-hemolytic [[streptococci]]). | ||
Note: Only | Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. DURICEF is generally effective in the eradication of [[streptococci]] from the oropharynx. However, data establishing the efficacy of DURICEF for the prophylaxis of subsequent rheumatic fever are not available. | ||
Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. | Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. | ||
Latest revision as of 23:29, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
DURICEF is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases:
Urinary tract infections caused byE. coli,P. mirabilis, and Klebsiella species.
Skin and skin structure infections caused by staphylococci and/or streptococci.
Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci).
Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. DURICEF is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of DURICEF for the prophylaxis of subsequent rheumatic fever are not available.
Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DURICEF and other antibacterial drugs, DURICEF should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050512s046,050527s022,050528s020lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.